T1	Person 0 3	Age
T2	Value 4 37	greater than or equal to 18 years
R1	Has_value Arg1:T1 Arg2:T2	
T3	Condition 44 46	RA
T4	Qualifier 66 120	1987 revised American College of Rheumatology criteria
R2	Has_qualifier Arg1:T3 Arg2:T4	
T5	Condition 125 153	sustained clinical remission
T6	Multiplier 154 175	for the last 6 months
R3	Has_multiplier Arg1:T5 Arg2:T6	
T7	Drug 214 224	etanercept
T8	Drug 226 236	infliximab
T9	Drug 241 251	adalimumab
T10	Multiplier 257 283	greater than or equal to 1
T11	Drug 284 289	DMARD
R4	Has_multiplier Arg1:T11 Arg2:T10	
*	OR T7 T8 T9
T12	Drug 291 303	methotrexate
T13	Drug 305 323	hydroxychloroquine
T14	Drug 325 338	sulfasalazine
T15	Drug 340 351	leflunomide
T16	Drug 353 364	minocycline
T17	Drug 366 378	cyclosporine
T18	Drug 380 392	azathioprine
T19	Drug 394 398	gold
T20	Drug 400 413	penicillamine
*	OR T20 T19 T18 T17 T16 T15 T14 T13 T12
T21	Scope 291 413	methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, minocycline, cyclosporine, azathioprine, gold, penicillamine
R5	Subsumes Arg1:T11 Arg2:T21	
T22	Measurement 416 421	DAS28
T23	Value 432 445	less than 2.6
R6	Has_value Arg1:T22 Arg2:T23	
T24	Multiplier 460 487	over the preceding 6 months
T25	Multiplier 494 506	at least one
T26	Procedure 507 512	visit
T27	Procedure 454 459	visit
T28	Multiplier 446 459	on each visit
R7	multi Arg1:T28 Arg2:T27	
R10	Has_multiplier Arg1:T26 Arg2:T25	
T29	Temporal 513 541	2-4 months before enrollment
T30	Non-representable 543 705	If there is no visit 6 months before enrollment, the nearest visit in the 6-12 month period before enrollment should be considered and have a DAS28 less than 2.6.
R11	Has_temporal Arg1:T26 Arg2:T29	
R8	Has_multiplier Arg1:T22 Arg2:T28	
R9	Has_multiplier Arg1:T22 Arg2:T24	
